Results 51 to 60 of about 141,326 (319)

Clinical factors associated with pneumocystis pneumonia despite its primary prophylaxis: When to stop prophylaxis?

Arthritis &Rheumatology, Accepted Article.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim, Se Rim Choi, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park   +5 more
wiley   +1 more source

Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. [PDF]

PLoS ONE, 2016
To estimate mortality rates and prognostic factors in HIV-positive patients who started combination antiretroviral therapy between 1996-1999 and survived for more than ten years.We used data from 18 European and North American HIV cohort studies ...
Adam Trickey, Margaret T May, Janne Vehreschild, Niels Obel, Michael John Gill, Heidi Crane, Christoph Boesecke, Hasina Samji, Sophie Grabar, Charles Cazanave, Matthias Cavassini, Leah Shepherd, Antonella d'Arminio Monforte, Colette Smit, Michael Saag, Fiona Lampe, Vicky Hernando, Marta Montero, Robert Zangerle, Amy C Justice, Timothy Sterling, Jose Miro, Suzanne Ingle, Jonathan A C Sterne, Antiretroviral Therapy Cohort Collaboration (ART-CC)   +24 more
doaj   +1 more source

The cost of antiretroviral therapy in Haiti [PDF]

Cost Effectiveness and Resource Allocation, 2008
We determined direct medical costs, overhead costs, societal costs, and personnel requirements for the provision of antiretroviral therapy (ART) to patients with AIDS in Haiti.We examined data from 218 treatment-naïve adults who were consecutively initiated on ART at the GHESKIO Center in Port-au-Prince, Haiti between December 23, 2003 and May 20, 2004
Daniel W. Fitzgerald, Patrice Severe, Bruce R. Schackman, Jean W. Pape, Paul Leger, Sidney Atwood, Cynthia Riviere, Serena P. Koenig   +7 more
openaire   +4 more sources

Toward information resilience: Applying intersectionality to the HIV/AIDS information practices of Black sexual minority men

Journal of the Association for Information Science and Technology, EarlyView.
Abstract Using intersectionality as a critical theoretical framework and analytical tool, this study investigated the HIV/AIDS information practices of Black sexual minority men (SMM). Twenty‐two Black SMM were interviewed about their HIV/AIDS‐related information practices.
Megan Threats
wiley   +1 more source

Sociodemographic and health systems determinants of antiretroviral therapy adherence among human immunodeficiency virus-positive patients in the Volta Region of Ghana: A multi-centre study

SAGE Open Medicine
Objectives: Optimal adherence to antiretroviral therapy is required for viral load suppression. This study investigated the sociodemographic (age, sex, marital status, level of education, monthly income, settlement type, distance to the antiretroviral ...
Elvis Enowbeyang Tarkang, Emmanuel Manu, Fortress Yayra Aku, Judith Anaman-Torgbor, Nelisiwe Khuzwayo   +4 more
doaj   +1 more source

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. [PDF]

PLoS Pathogens, 2007
Current antiretroviral therapy is effective in suppressing but not eliminating HIV-1 infection. Understanding the source of viral persistence is essential for developing strategies to eradicate HIV-1 infection.
Frank Maldarelli, Sarah Palmer, Martin S King, Ann Wiegand, Michael A Polis, JoAnn Mican, Joseph A Kovacs, Richard T Davey, Diane Rock-Kress, Robin Dewar, Shuying Liu, Julia A Metcalf, Catherine Rehm, Scott C Brun, George J Hanna, Dale J Kempf, John M Coffin, John W Mellors   +17 more
doaj   +1 more source

The Effects of Latent Infection on the Dynamics of HIV [PDF]

Differential Equations and Dynamical Systems, 3, 2016, 2013
One way in which the human immunodeficiency virus (HIV-1) replicates within a host is by infecting activated CD4+ T-cells, which then produce additional copies of the virus. Even with the introduction of antiretroviral drug therapy, which has been very successful over the past decade, a large obstacle to the complete eradication of the virus is the ...
arxiv   +1 more source

Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Moxifloxacin is a priority drug for treating rifampicin‐resistant tuberculosis (RR‐TB). We assessed the pharmacokinetics of a child‐friendly, dispersible 100 mg tablet moxifloxacin formulation (dispersed in water) compared to the standard 400 mg non‐dispersible formulation (crushed and suspended in water) in children and evaluated current dosing ...
Megan Palmer, Yuanxi Zou, Anneke C. Hesseling, Louvina van der Laan, Ingrid Courtney, Aarti A. Kinikar, Naresh Sonkawade, Mandar Paradkar, Vandana Kulkarni, Dessa Jean O. Casalme, Melchor V. G. Frias, Heather Draper, Lubbe Wiesner, Mats O. Karlsson, Paolo Denti, Elin M. Svensson, Anthony J. Garcia‐Prats   +16 more
wiley   +1 more source

A TB-HIV/AIDS coinfection model and optimal control treatment [PDF]

Discrete Contin. Dyn. Syst. 35 (2015), no. 9, 4639--4663, 2015
We propose a population model for TB-HIV/AIDS coinfection transmission dynamics, which considers antiretroviral therapy for HIV infection and treatments for latent and active tuberculosis. The HIV-only and TB-only sub-models are analyzed separately, as well as the TB-HIV/AIDS full model.
arxiv   +1 more source

Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims This review aimed to synthesise the evidence related to the incidence of serious and non‐serious adverse events with the use of monoclonal antibodies (mAbs) among COVID‐19 patients. Methods Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID‐19 regardless of ...
Htet Htet, Han You Kyung, Ismail Abdul Sattar Burud, Heethal Jaiprakash, Thiruselvi Subramaniam, Igor Iezhitsa, Renu Agarwal   +6 more
wiley   +1 more source